07:42 AM EDT, 09/16/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Monday interim results from its phase 2 study of its experimental bladder cancer therapy, TAR-200, showed in combination with chemotherapy using cetrelimab, TAR-200 demonstrated a nearly double pathologic complete response to using chemotherapy alone on patients with muscle-invasive bladder cancer.

Treatment-related adverse events occurred in 72% of patients treated with TAR-200 combined with cetrelimab, and 44% of patients treated with cetrelimab alone.

Of patients experiencing treatment-related adverse reactions, 9% discontinued treatments with TAR-200, while 8% discontinued treatment in the combination with chemotherapy. No patients discontinued treatment when treated with cetrelimab alone, the company said.

Price: 165.81, Change: +0.29, Percent Change: +0.18